The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer.
Farshid Dayyani
No relevant relationships to disclose
Andreas Varkaris
No relevant relationships to disclose
John C. Araujo
No relevant relationships to disclose
Jian H. Song
No relevant relationships to disclose
Geralyn C. Trudel
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christopher Logothetis
No relevant relationships to disclose
Gary E. Gallick
No relevant relationships to disclose